Caribou Biosciences Halts Off-the-Shelf CRISPR CAR-T Programs for Lymphoma and Myeloma After Failing to Fund Phase 3 Trial

Caribou Biosciences is ending its off-the-shelf CAR-T programs after failing to fund a phase 3 lymphoma trial. What patients should know.

Have A Referral?